Recent advances in the development of small-molecule CCR5 inhibitors for HIV.
CCR5 (C-C chemokine receptor type 5) is a chemokine receptor that has been identified as a major HIV co-receptor in viral entry and therefore is a highly validated target for the development of new anti-HIV drugs. Here, we discuss the insights gained so far relevant to the development of small-molecule CCR5 inhibitors for the treatment of HIV, and highlight small-molecule CCR5 inhibitors that are currently under preclinical and clinical trials.
Liu
Tao
T
ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. lt601@zju.edu.cn
Weng
Zhiyong
Z
Dong
Xiaowu
X
Hu
Yongzhou
Y
D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D054852:Small Molecule Libraries / Q000737:chemistry* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D065100:CCR5 Receptor Antagonists; D054852:Small Molecule Libraries